Terms: = Prostate cancer AND BLM, MGC131620, 641, ENSG00000197299, MGC131618, RECQ2, RECQL2, RECQL3, MGC126616, BS AND Prognosis
17 results:
1. Development of machine learning prognostic models for overall survival of prostate cancer patients with lymph node-positive.
Peng ZH; Tian JH; Chen BH; Zhou HB; Bi H; He MX; Li MR; Zheng XY; Wang YW; Chong T; Li ZL
Sci Rep; 2023 Oct; 13(1):18424. PubMed ID: 37891423
[TBL] [Abstract] [Full Text] [Related]
2. PARP1 negatively regulates transcription of blm through its interaction with HSP90AB1 in prostate cancer.
Huang M; Chen L; Guo Y; Ruan Y; Xu H
J Transl Med; 2023 Jul; 21(1):445. PubMed ID: 37415147
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in prostate cancer Patients.
Zhang D; Xu X; Wei Y; Chen X; Li G; Lu Z; Zhang X; Ren X; Wang S; Qin C
Cancer Control; 2022; 29():10732748221129451. PubMed ID: 36283420
[TBL] [Abstract] [Full Text] [Related]
4. RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma.
Li Y; He X; Zhang X; Xu Y; Chen W; Liu X; Xu X
Clin Exp Med; 2022 May; 22(2):229-243. PubMed ID: 34275027
[TBL] [Abstract] [Full Text] [Related]
5. Application of Diffusion Weighted Imaging in prostate cancer Bone Metastasis: Detection and Therapy Evaluation.
Gong XQ; Tao YY; Wang R; Liu N; Huang XH; Zheng J; Yang C; Yang L; Zhang XM
Anticancer Agents Med Chem; 2021; 21(15):1950-1956. PubMed ID: 33461473
[TBL] [Abstract] [Full Text] [Related]
6. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent prostate cancer.
Jin Y; Wang L; Lou H; Song C; He X; Ding M
Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
[TBL] [Abstract] [Full Text] [Related]
7. A Review of prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
Ahn T; Roberts MJ; Abduljabar A; Joshi A; Perera M; Rhee H; Wood S; Vela I
Mol Imaging Biol; 2019 Oct; 21(5):799-807. PubMed ID: 30617728
[TBL] [Abstract] [Full Text] [Related]
8. Baseline
García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
[TBL] [Abstract] [Full Text] [Related]
9.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract] [Full Text] [Related]
10. Expression of HMGB2 indicates worse survival of patients and is required for the maintenance of Warburg effect in pancreatic cancer.
Cai X; Ding H; Liu Y; Pan G; Li Q; Yang Z; Liu W
Acta Biochim Biophys Sin (Shanghai); 2017 Feb; 49(2):119-127. PubMed ID: 28069585
[TBL] [Abstract] [Full Text] [Related]
11. Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients.
Brunello A; Fontana A; Zafferri V; Panza F; Fiduccia P; Basso U; Copetti M; Lonardi S; Roma A; Falci C; Monfardini S; Cella A; Pilotto A; Zagonel V
J Cancer Res Clin Oncol; 2016 May; 142(5):1069-77. PubMed ID: 26758276
[TBL] [Abstract] [Full Text] [Related]
12. [Outcomes and predictors of T3a prostate cancer treated by permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy].
Mai Z; Yan W; Li H; Zhou Y; Zhou Z; Chen J
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):765-70. PubMed ID: 25573217
[TBL] [Abstract] [Full Text] [Related]
13. Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose-response meta-analysis of 36,927 patients.
Hu MB; Xu H; Bai PD; Jiang HW; Ding Q
Med Oncol; 2014 Feb; 31(2):829. PubMed ID: 24390417
[TBL] [Abstract] [Full Text] [Related]
14. A common nonsense mutation of the blm gene and prostate cancer risk and survival.
Antczak A; Kluźniak W; Wokołorczyk D; Kashyap A; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Masojć B; Górski B; Gromowski T; Nagorna A; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Borkowski T; Borkowski A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Domagała P; Stawicka M; Milecki P; Akbari MR; Narod SA; Lubiński J; Cybulski C; ; ; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała W; Chosia M; van de Wetering T; Serrano-Fernández P; Puszyński M; Soczawa M; Switała J; Archimowicz S; Kordowski M; Zyczkowski M; Borówka A; Bagińska J; Krajka K; Szwiec M; Haus O; Janiszewska H; Stembalska A; Sąsiadek MM
Gene; 2013 Dec; 532(2):173-6. PubMed ID: 24096176
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.
Meirelles GS; Schöder H; Ravizzini GC; Gönen M; Fox JJ; Humm J; Morris MJ; Scher HI; Larson SM
Clin Cancer Res; 2010 Dec; 16(24):6093-9. PubMed ID: 20975102
[TBL] [Abstract] [Full Text] [Related]
16. Four prognostic indices in advanced prostate cancer patients, under palliative androgen deprivation treatment.
Bantis A; Zissimopoulos A; Kalaitzis C; Giannakopoulos S; Sountoulides P; Parmenopoulou V; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2008; 11(1):21-5. PubMed ID: 18392222
[TBL] [Abstract] [Full Text] [Related]
17. Surgical treatment for pathologic fracture.
Wedin R
Acta Orthop Scand Suppl; 2001 Jun; 72(302):2p., 1-29. PubMed ID: 11582636
[TBL] [Abstract] [Full Text] [Related]
